252 related articles for article (PubMed ID: 33053689)
21. Nivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression.
Sun LM; Liu YC; Li W; Liu S; Liu HX; Li LW; Ma R
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1198-1205. PubMed ID: 28387913
[TBL] [Abstract][Full Text] [Related]
22. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.
El-Senduny FF; Badria FA; El-Waseef AM; Chauhan SC; Halaweish F
Tumour Biol; 2016 Jan; 37(1):685-98. PubMed ID: 26242260
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and antitumour activity of a new trinuclear platinum compound [{cis-PtCl(NH3)2μ {trans-Pt(3-hydroxypyridine)2H2N(CH2)5NH2)2}] Cl4 in human ovarian cancer cells.
Hamad SA; Beale P; Yu JQ; Huq F
Anticancer Res; 2014 Apr; 34(4):1923-9. PubMed ID: 24692727
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines.
Tayyem H; Huq F; Yu JQ; Beale P; Fisher K
ChemMedChem; 2008 Jan; 3(1):145-51. PubMed ID: 17963210
[TBL] [Abstract][Full Text] [Related]
25. Sanguinarine enhances cisplatin sensitivity via glutathione depletion in cisplatin-resistant ovarian cancer (A2780) cells.
Sarkhosh-Inanlou R; Molaparast M; Mohammadzadeh A; Shafiei-Irannejad V
Chem Biol Drug Des; 2020 Feb; 95(2):215-223. PubMed ID: 31512406
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
27. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
28. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
29. Studies on synthesis, activity and binding with DNA of a new trinuclear platinum compound [{trans-PtCl(NH3)2}2{trans-Pt(thiazole)2}{H2N(CH2)(6NH2}2]Cl3(NO3).
Al-Shuneigat J; Qing Y; Beale P; Fisher K; Huq F
Med Chem; 2011 Jan; 7(1):1-8. PubMed ID: 21235513
[TBL] [Abstract][Full Text] [Related]
30. Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method.
Gong F; Peng X; Zeng Z; Yu M; Zhao Y; Tong A
Mol Cell Biochem; 2011 Feb; 348(1-2):141-7. PubMed ID: 21080034
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
Wang M; Ma X; Wang J; Wang L; Wang Y
Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
[TBL] [Abstract][Full Text] [Related]
32. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
33. Synthetic isothiocyanate indole-3-ethyl isothiocyanate (homoITC) enhances sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to cisplatin.
Stehlik P; Paulikova H; Hunakova L
Neoplasma; 2010; 57(5):473-81. PubMed ID: 20568902
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
35. Overcoming multidrug resistance by activating unfolded protein response of the endoplasmic reticulum in cisplatin-resistant A2780/CisR ovarian cancer cells.
Jung E; Koh D; Lim Y; Shin SY; Lee YH
BMB Rep; 2020 Feb; 53(2):88-93. PubMed ID: 31401981
[TBL] [Abstract][Full Text] [Related]
36. Synergism from combination of cisplatin and a trans-platinum compound in ovarian cancer cell lines.
Alshehri A; Beale P; Yu JQ; Huq F
Anticancer Res; 2010 Nov; 30(11):4547-53. PubMed ID: 21115904
[TBL] [Abstract][Full Text] [Related]
37. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
[TBL] [Abstract][Full Text] [Related]
38. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
40. Glaucocalyxin B Attenuates Ovarian Cancer Cell Growth and Cisplatin Resistance In Vitro via Activating Oxidative Stress.
Zhang T; Xu C; Zheng P; Zhang X; Qiu C; Wu F; Chen J; Xiao Z; Zhu J; Zhang J; Zou P; Ni D
Oxid Med Cell Longev; 2022; 2022():6324292. PubMed ID: 35251480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]